



9 July 2012

ASX Market Announcements
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

Molecular Discovery Systems Signs Collaboration Agreement with Peter MacCallum Cancer Centre

BPH Energy Limited (ASX:**BPH**) investee company Molecular Discovery Systems Limited ("**MDS**") is pleased to announce the signing of a research collaboration agreement with the Peter MacCallum Cancer Centre ("**Peter Mac**"). This collaborative research program is aimed at the discovery and development of new cancer drugs that normalise the function of the key tumour suppressor p53.

David Breeze, Chairman of MDS, said, "we are pleased to be engaged in this collaborative research with Peter Mac. By working with scientists who have been at the forefront of p53 research for two decades, we are confident that this collaboration has ample potential to deliver highly-favourable outcomes".

Under the agreement compounds with the desired anti-cancer activity will be identified and developed by combining the advanced drug screening platform at MDS with procedures pioneered by laboratory researchers at Peter Mac.

A spokesperson for Peter Mac stated, "we are excited to be working with MDS — it is important for us to build strong relationships with innovative Australian companies, to accelerate the translation of our research findings into new treatments for cancer patients".

Yours sincerely,

A handwritten signature in black ink, appearing to read "D. Breeze".

David Breeze
Chairman

For Further Information

David Breeze
Chairman
tel: +61 (0) 8 9328 8366

david@bphenergy.com.au

BPH Energy Limited ACN 95 912 002
PO Box 317, North Perth, Western Australia 6906
14 View Street, North Perth, Western Australia 6006
admin@bphenergy.com.au www.bphenergy.com.au
T: +61 8 9328 8366 F: +61 8 9328 8733



Background:

MDS:

MDS has core expertise in high-content and high-throughput imaging and analysis, providing services for researcher worldwide. Central to the MDS drug screening platform is a semi-automated cellular imaging and analysis facility that provides access to complex drug targets. BPH Energy has a 20% residual interest in MDS after the spin-off of MDS in 2010. BPH Energy is working towards a listing of MDS on the Australian Securities Exchange.

Peter MacCallum Cancer Centre:

Peter Mac is Australia's only public hospital solely dedicated to cancer, a national leader in multi-disciplinary cancer care, and a national and international leader in laboratory, clinical and translational research.

Peter Mac's research laboratories are home to over 400 scientists and support staff working with sophisticated resources and facilities in a strong and collegiate environment that fosters innovative and collaborative research.